When a pathology-related claim lands on an attorney's desk, the instinct is to go straight to the diagnosis: was it right or wrong? That instinct is understandable — but it misses where many of the most consequential failures actually occur.
The Pathology Vulnerability Assessment (PVA) starts upstream. Before asking whether the pathologist interpreted the slide correctly, it asks a more fundamental question: was the process that produced that slide sound enough to trust the diagnosis in the first place?
"The pathologist can only diagnose what is on the slide. What is on the slide is the result of every decision, action, and protocol that came before the microscope was ever involved."
The Three-Phase Diagnostic Pathway
The PVA methodology organizes the complete pathology diagnostic pathway into four domains. Each phase is governed by professional standards — primarily CAP (College of American Pathologists) protocols and CLIA requirements — and each represents a distinct opportunity for procedural failure.
Pre-Analytical
Everything from the clinical order through specimen receipt at the laboratory: collection, labeling, chain of custody, fixation, transport, and accessioning. Published laboratory quality literature consistently identifies this phase as the most common source of laboratory error.
Analytical
The laboratory phase: gross examination and sampling, histologic processing, staining, IHC and ancillary testing, and quality control. The most consequential step is gross examination — the pathologist can only diagnose what was sampled.
Post-Analytical
The report and everything after: diagnosis completeness, CAP synoptic protocol compliance, critical value notification, specimen retention, and clinical consultation between the pathologist and treating physician.
Diagnostic Discordance Review
When multiple pathology reports, outside consultations, amended reports, or second opinions exist, Sentinel identifies whether they contain materially different diagnostic conclusions. Sentinel does not determine which diagnosis is correct — it classifies the discordance and advises counsel whether it warrants physician pathologist review or targeted discovery. This is the PVA’s cost-triage function for cases involving conflicting pathology opinions.
The Fourth Domain: Diagnostic Discordance Review
Many pathology-related cases already involve conflicting opinions — an original report and a second opinion that disagree, an amended diagnosis that changed the clinical picture, or an outside consultation that reached a different conclusion than the original pathologist. The PVA addresses this directly through its fourth domain.
Sentinel does not independently review glass slides, render a diagnosis, or determine which pathologist is correct. That is the exclusive domain of a physician pathologist. What the Diagnostic Discordance Review does is identify whether the pathology record contains materially different diagnostic conclusions, classify the significance of that discordance, and advise counsel whether it warrants physician pathologist review — before counsel commits to that expense.
An attorney who has two conflicting pathology opinions does not know if the difference matters or whether it justifies retaining a physician pathologist. A Screening PVA answers that question at $1,250 — before the attorney spends $5,000–$15,000 on a physician expert. That is the fourth domain’s specific value: it tells you whether the discordance is worth pursuing before you commit to pursuing it.
Discordance findings are classified across five levels: no discordance identified, terminology variation only, potentially material discordance, material diagnostic discordance, and unresolved discordance. Each classification carries a specific recommendation for next steps — from no further action to physician pathologist review to targeted discovery.
What a PVA Is Not
A PVA is not a diagnostic second opinion. It does not require proving that the pathologist's microscopic interpretation was wrong. In fact, some of the most actionable PVA findings occur in cases where the microscopic diagnosis was entirely correct — because the process that produced it was fundamentally compromised.
This distinction matters strategically. A plaintiff attorney who can demonstrate that the laboratory process was defective does not need to win a battle of microscopic interpretation between competing pathologists. The process failure stands independently.
A PVA can identify settlement leverage in cases where diagnostic error is difficult to prove — because a process failure upstream of the diagnosis is independently actionable, regardless of whether the final pathologic interpretation was defensible.
The PVA and Texas Chapter 74
Texas Chapter 74 requires a qualifying expert report within 120 days of filing a health care liability claim. Before that clock starts — and before committing to the cost of a testifying physician expert — attorneys need to know whether a viable pathology theory exists and where it lives in the record.
The Tier I PVA delivers exactly that: a structured record review across all four PVA domains, a written Screening PVA Report, and a case posture designation that tells you whether to proceed, how to proceed, and what a physician expert should be examining. That analysis becomes the briefing document your physician expert needs to produce a compliant, defensible report efficiently.
Who Performs the PVA
Robert Weir holds the PA(ASCP) credential — Pathologists' Assistant, American Society for Clinical Pathology — with 28 years of quaternary surgical pathology practice and 15 years as laboratory operations manager at two private surgical pathology laboratories. The PVA methodology is built on direct, hands-on expertise with every step of the diagnostic pathway it audits.
Physician experts who testify on diagnostic accuracy are typically strong on what the slide showed. They are rarely strong on what happened before the slide existed. That is precisely where the PVA operates — and where Sentinel's laboratory-operations experience provides a distinct and highly focused form of review.
The Screening PVA Outcomes
Every Tier I engagement produces a written Screening PVA Report with one of five case posture designations:
- Consistent with Standard of Care — no material vulnerabilities identified; final Tier I determination, no Case Development PVA recommended
- Minor Vulnerability Identified — departure identified; unlikely to independently support liability on current record
- Significant Vulnerability Identified — material departure that may have affected the diagnostic process or outcome; Case Development PVA recommended
- Critical Vulnerability Identified — fundamental failure in the diagnostic pathway directly relevant to the clinical outcome; Case Development PVA strongly recommended
- Indeterminate — additional records required before a posture determination can be reached
The Tier I Screening PVA fee is $1,250 flat, credited in full toward Tier II if findings warrant proceeding. It is a complete, standalone product at every outcome.
The PVA answers the question you need answered before filing: is there a viable pathology theory in this record, where does it live, and what does it mean for the case? That analysis costs $1,250 and can save multiples of that in expert fees on cases that do not have a viable theory — and strengthen those that do.